A novel subtilin-like lantibiotics subtilin JS-4 produced by Bacillus subtilis JS-4, and its antibacterial mechanism against Listeria monocytogenes

Wei, Zhaohui; Shan, Chengjun; Zhang, Lixia; Ge, Da'e; Wāng, Ying; Xia, Xiufang; Liu, Xiaoli; Zhou, Jing

doi:10.1016/j.lwt.2021.110993

Cited by 16 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specific to Listeria , several antimicrobial molecules secreted by Bacillaceae strains have been shown to mitigate LM growth in culture [ 62 , 64 , 69 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 ]. In particular, a subtilin-type bacteriocin peptide from Bacillus subtilis JS-4 was shown by confocal laser-scanning microscopy and electron microscopy to increase LM cell membrane permeability, trigger potassium ion leakage and pore formation, and damage cell membrane integrity [ 89 ]. Following oral LM challenge in mice and rats, administration of probiotic strains from the genera Lactobacillus , Lacticaseibacillus , Ligilactobacillus , and Lactococcus was associated with increased visceral organ bacterial clearance and reduced severity of infection [ 90 , 91 , 92 , 93 , 94 ].…”

Section: Discussionmentioning

confidence: 99%

The Probiotic Bacillus subtilis MB40 Improves Immunity in a Porcine Model of Listeriosis

Garvey,

Emami,

Guice

et al. 2023

Microorganisms

View full text Add to dashboard Cite

Probiotics for humans and direct-fed microbials for livestock are increasingly popular dietary ingredients for supporting immunity. The aim of this study was to determine the effects of dietary supplementation of Bacillus subtilis MB40 (MB40) on immunity in piglets challenged with the foodborne pathogen Listeria monocytogenes (LM). Three-week-old piglets (n = 32) were randomly assigned to four groups: (1) basal diet, (2) basal diet with LM challenge, (3) MB40-supplemented diet, and (4) MB40-supplemented diet with LM challenge. Experimental diets were provided throughout a 14-day (d) period. On d8, piglets in groups 2 and 4 were intraperitoneally inoculated with LM at 108 CFU/mL per piglet. Blood samples were collected at d1, d8, and d15 for biochemical and immune response profiling. Animals were euthanized and necropsied at d15 for liver and spleen bacterial counts and intestinal morphological analysis. At d15, LM challenge was associated with increased spleen weight (p = 0.017), greater circulating populations of neutrophils (p = 0.001) and monocytes (p = 0.008), and reduced ileal villus height to crypt depth ratio (p = 0.009), compared to non-challenged controls. MB40 supplementation reduced LM bacterial counts in the liver and spleen by 67% (p < 0.001) and 49% (p < 0.001), respectively, following the LM challenge, compared to the basal diet. MB40 supplementation was also associated with decreased circulating concentrations of monocytes (p = 0.007). Altogether, these data suggest that MB40 supplementation is a safe and well-tolerated approach to enhance immunity during systemic Listeria infection.

show abstract

Section: Discussionmentioning

confidence: 99%

The Probiotic Bacillus subtilis MB40 Improves Immunity in a Porcine Model of Listeriosis

Garvey,

Emami,

Guice

et al. 2023

Microorganisms

View full text Add to dashboard Cite

show abstract

“…Subtilin JS-4 retained >90% and 86.1% of its antibacterial activity even after a 30 min exposure to 80–100 °C and 121 °C, respectively, indicating considerable thermostability. Subtilin JS-4 was also rapidly inactivated by proteolytic enzymes including proteinase K, trypsin, papain and pepsin [ 91 ]. It also showed a broad antimicrobial spectrum against Gram-positive bacteria.…”

Section: Antibacterial Substances Secreted By Bacillus Lich...mentioning

confidence: 99%

“…It also showed a broad antimicrobial spectrum against Gram-positive bacteria. Subtilin JS-4 inhibited the growth of foodborne bacterium L. monocytogenes by increasing cell membrane permeability, triggering pore formation and K + leakage, and damaging cell membrane integrity, which eventually disrupted the membrane and cellular structure [ 91 ] ( Figure 2 ).…”

Section: Antibacterial Substances Secreted By Bacillus Lich...mentioning

confidence: 99%

See 1 more Smart Citation

Bacillus licheniformis: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical Applications

Shleeva,

Kondratieva,

Kaprelyants

2023

Pharmaceutics

View full text Add to dashboard Cite

Bacillus licheniformis produces several classes of antimicrobial substances, including bacteriocins, which are peptides or proteins with different structural composition and molecular mass: ribosomally synthesized by bacteria (1.4–20 kDa), non-ribosomally synthesized peptides and cyclic lipopeptides (0.8–42 kDa) and exopolysaccharides (>1000 kDa). Different bacteriocins act against Gram-positive or Gram-negative bacteria, fungal pathogens and amoeba cells. The main mechanisms of bacteriocin lytic activity include interaction of peptides with membranes of target cells resulting in structural alterations, pore-forming, and inhibition of cell wall biosynthesis. DNase and RNase activity for some bacteriocines are also postulated. Non-ribosomal peptides are synthesized by special non-ribosomal multimodular peptide synthetases and contain unnatural amino acids or fatty acids. Their harmful effect is due to their ability to form pores in biological membranes, destabilize lipid packaging, and disrupt the peptidoglycan layer. Lipopeptides, as biosurfactants, are able to destroy bacterial biofilms. Secreted polysaccharides are high molecular weight compounds, composed of repeated units of sugar moieties attached to a carrier lipid. Their antagonistic action was revealed in relation to bacteria, viruses, and fungi. Exopolysaccharides also inhibit the formation of biofilms by pathogenic bacteria and prevent their colonization on various surfaces. However, mechanism of the harmful effect for many secreted antibacterial substances remains unknown. The antimicrobial activity for most substances has been studied in vitro only, but some substances have been characterized in vivo and they have found practical applications in medicine and veterinary. The cyclic lipopeptides that have surfactant properties are used in some industries. In this review, special attention is paid to the antimycobacterials produced by B. licheniformis as a possible approach to combat multidrug-resistant and latent tuberculosis. In particular, licheniformins and bacitracins have shown strong antimycobacterial activity. However, the medical application of some antibacterials with promising in vitro antimycobacterial activity has been limited by their toxicity to animals and humans. As such, similar to the enhancement in the antimycobacterial activity of natural bacteriocins achieved using genetic engineering, the reduction in toxicity using the same approach appears feasible. The unique capability of B. licheniformis to synthesize and produce a range of different antibacterial compounds means that this organism can act as a natural universal vehicle for antibiotic substances in the form of probiotic cultures and strains to combat various types of pathogens, including mycobacteria.

show abstract

“…Nisin and lacticin were also active against clinical isolates of mycobacteria in vitro, including M. tuberculosis [199,200]. B. licheniformis MCC 2512 T produced a natural variant of nisin, subtilin [90,91], which was active against M. tuberculosis [201] (Figure 2).…”

Section: Antimicrobial Substances Of B Licheniformis Active Against M...mentioning

confidence: 99%

Bacillus licheniformis – A Perspective for Medical Applications Producer of Variety of Antimicrobial Substances Including Antimycobacterials

Shleeva,

Kondrateva,

Kaprelyants

2023

Preprint

View full text Add to dashboard Cite

Bacillus licheniformis produce several classes of antimicrobial substances which are mainly either peptides or proteins. Among of them bacteriocins - peptides or proteins of different structural composition including synthesized by bacteria ribosomally; non-ribosomally synthesized peptides and cyclic lipopeptides; exopolysaccharides. Different representatives of these classes act against Gram-positive, Gram-negative bacteria, fungal pathogens and amoebae cells. In this review, a detailed classification of antimicrobial substances produced by B. licheniformis based on their chemical structure and mode of the synthesis and activity is presented. For some (rather limited number) of secreted antimicrobials mechanism of their harmful effect on the target cells is established, however, for many of them it remains unknown. The antimicrobial activity for most substances was studied in vitro only, however some substances were characterized in vivo and are found practical applications in medicine and veterinary. The cyclic lipopeptides with surfactant properties are applied in industry. In this review, a special attention on antimycobacterials produced by B. licheniformis is made as a possible approach to combat multidrug resistant and latent tuberculosis. Indeed, a number of peptides and proteins revealed strong antimycobacterial activity. However, medical application of some bacteriocins with promising in vitro antimycobacterial activity is limited by their toxicity for animals and humans. In this connection, similarly with the enhancement of the antimycobacterial activity of natural bacteriocins using genetic engineering, reduction of the toxicity by the same approach looks feasible. A unique capability of B. licheniformis to synthesize and produce a bouquet of different antibacterial compounds allow to consider this organism as a universal natural vehicle for antibiotic substances in form of probiotic cultures strains to combat various types of pathogens including mycobacteria.

show abstract

A novel subtilin-like lantibiotics subtilin JS-4 produced by Bacillus subtilis JS-4, and its antibacterial mechanism against Listeria monocytogenes

Cited by 16 publications

References 27 publications

The Probiotic Bacillus subtilis MB40 Improves Immunity in a Porcine Model of Listeriosis

The Probiotic Bacillus subtilis MB40 Improves Immunity in a Porcine Model of Listeriosis

Bacillus licheniformis: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical Applications

Bacillus licheniformis – A Perspective for Medical Applications Producer of Variety of Antimicrobial Substances Including Antimycobacterials

Contact Info

Product

Resources

About